Jason Robert Guertin, Élodie Bénard, Marie-Claude Aubin, Vakaramoko (Karam) Diaby, Alice Dragomir, Eric Latimer, Jean-Éric Tarride, Don Husereau
The Consolidated Health Economic Evaluation Reporting Standards (CHEERS) provide guidance for health technology assessment bodies to use when reporting economic evaluations. The most recent edition, CHEERS 2022, is a 28-item reporting checklist that was developed in consultation with a broad range of stakeholders. CHEERS 2022 has been translated into French so it can be used more widely and improve consistency in economic evaluations among the international health technology assessment community.
{"title":"French Translation of the 2022 Version of the Consolidated Health Economic Evaluation Reporting Standards (CHEERS) Statement","authors":"Jason Robert Guertin, Élodie Bénard, Marie-Claude Aubin, Vakaramoko (Karam) Diaby, Alice Dragomir, Eric Latimer, Jean-Éric Tarride, Don Husereau","doi":"10.51731/cjht.2023.754","DOIUrl":"https://doi.org/10.51731/cjht.2023.754","url":null,"abstract":"The Consolidated Health Economic Evaluation Reporting Standards (CHEERS) provide guidance for health technology assessment bodies to use when reporting economic evaluations. The most recent edition, CHEERS 2022, is a 28-item reporting checklist that was developed in consultation with a broad range of stakeholders. CHEERS 2022 has been translated into French so it can be used more widely and improve consistency in economic evaluations among the international health technology assessment community.","PeriodicalId":9437,"journal":{"name":"Canadian Journal of Health Technologies","volume":"243 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-10-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135942722","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
For patients with knee osteoarthritis (OA), radiofrequency ablation may reduce pain and improve function compared to other nonsurgical interventions without increasing adverse events.
There is insufficient evidence to suggest that radiofrequency ablation reduces pain or improves function among patients with chronic hip pain.
We did not find any studies or guidelines on the clinical effectiveness of radiofrequency ablation for treating chronic shoulder pain that met the inclusion criteria for this review.
Three guidelines conditionally recommend the use of radiofrequency ablation for patients with knee OA, and 1 guideline conditionally recommends the use of radiofrequency ablation for hip joint pain following diagnostic blocks.
{"title":"Radiofrequency Ablation for Chronic Knee, Hip, and Shoulder Pain","authors":"Amanda Shane, Sharon Bailey","doi":"10.51731/cjht.2023.750","DOIUrl":"https://doi.org/10.51731/cjht.2023.750","url":null,"abstract":"
 For patients with knee osteoarthritis (OA), radiofrequency ablation may reduce pain and improve function compared to other nonsurgical interventions without increasing adverse events.
 There is insufficient evidence to suggest that radiofrequency ablation reduces pain or improves function among patients with chronic hip pain.
 We did not find any studies or guidelines on the clinical effectiveness of radiofrequency ablation for treating chronic shoulder pain that met the inclusion criteria for this review.
 Three guidelines conditionally recommend the use of radiofrequency ablation for patients with knee OA, and 1 guideline conditionally recommends the use of radiofrequency ablation for hip joint pain following diagnostic blocks.
","PeriodicalId":9437,"journal":{"name":"Canadian Journal of Health Technologies","volume":"49 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-10-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"136357939","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
For adults with moderate to severe pain in the emergency department (ED), IV acetaminophen may offer similar levels of pain relief and a similar risk of adverse events as oral acetaminophen or IV nonsteroidal anti-inflammatory drugs (NSAIDs).
For adults with moderate to severe pain in the ED, IV acetaminophen may offer a similar or modestly lower level of pain relief, and a lower risk of adverse events, when compared to IV opioids.
We did not find any studies on the cost-effectiveness of IV acetaminophen compared to oral acetaminophen, IV NSAIDs, or IV opioids for treating patients with moderate to severe pain in the ED that met our inclusion criteria.
One guideline recommends IV NSAIDs for the initial management of moderate to severe pain for patients in the ED. IV acetaminophen is recommended instead of IV opioids alone.
{"title":"IV Acetaminophen for Acute Pain in Emergency Departments","authors":"Kendra Brett, Melissa Severn","doi":"10.51731/cjht.2023.749","DOIUrl":"https://doi.org/10.51731/cjht.2023.749","url":null,"abstract":"
 For adults with moderate to severe pain in the emergency department (ED), IV acetaminophen may offer similar levels of pain relief and a similar risk of adverse events as oral acetaminophen or IV nonsteroidal anti-inflammatory drugs (NSAIDs).
 For adults with moderate to severe pain in the ED, IV acetaminophen may offer a similar or modestly lower level of pain relief, and a lower risk of adverse events, when compared to IV opioids.
 We did not find any studies on the cost-effectiveness of IV acetaminophen compared to oral acetaminophen, IV NSAIDs, or IV opioids for treating patients with moderate to severe pain in the ED that met our inclusion criteria.
 One guideline recommends IV NSAIDs for the initial management of moderate to severe pain for patients in the ED. IV acetaminophen is recommended instead of IV opioids alone.
","PeriodicalId":9437,"journal":{"name":"Canadian Journal of Health Technologies","volume":"124 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-10-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"134943642","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
In 2017, the CADTH Canadian Drug Expert Committee recommended that budesonide extended release (with multi-matrix system) not be reimbursed for the induction of remission in patients with active mild to moderate ulcerative colitis based on limitations in the evidence at that time.
The limited primary clinical evidence (i.e., 1 randomized controlled trial) published since the literature searches conducted for the previous CADTH Reimbursement Review corroborates the clinical findings of that report. The evidence demonstrates that budesonide extended release is more effective for inducing remission in patients with mild to moderate ulcerative colitis compared to placebo.
No new clinical evidence was identified describing head-to-head comparisons of budesonide extended release with active therapies. Indirect comparative evidence between budesonide extended release and other active therapies suggests minimal or no difference in remission, clinical response, or adverse events.
Cost-effectiveness evidence from 1 study conducted in the Netherlands indicates that budesonide extended release is a more effective and less costly second-line therapy versus aggregated comparators for patients with mild to moderate ulcerative colitis.
Evidence-based recommendations support the use of budesonide extended release for patients with mild to moderate ulcerative colitis who have not responded to 5-ASAs.
No clinical or cost-effectiveness evidence or evidence-based recommendations were found describing the use of budesonide extended release in patients with moderate to severe ulcerative colitis.
{"title":"Budesonide Extended Release for Ulcerative Colitis","authors":"Sara D. Khangura, Carolyn Spry","doi":"10.51731/cjht.2023.748","DOIUrl":"https://doi.org/10.51731/cjht.2023.748","url":null,"abstract":"
 In 2017, the CADTH Canadian Drug Expert Committee recommended that budesonide extended release (with multi-matrix system) not be reimbursed for the induction of remission in patients with active mild to moderate ulcerative colitis based on limitations in the evidence at that time.
 The limited primary clinical evidence (i.e., 1 randomized controlled trial) published since the literature searches conducted for the previous CADTH Reimbursement Review corroborates the clinical findings of that report. The evidence demonstrates that budesonide extended release is more effective for inducing remission in patients with mild to moderate ulcerative colitis compared to placebo.
 No new clinical evidence was identified describing head-to-head comparisons of budesonide extended release with active therapies. Indirect comparative evidence between budesonide extended release and other active therapies suggests minimal or no difference in remission, clinical response, or adverse events.
 Cost-effectiveness evidence from 1 study conducted in the Netherlands indicates that budesonide extended release is a more effective and less costly second-line therapy versus aggregated comparators for patients with mild to moderate ulcerative colitis.
 Evidence-based recommendations support the use of budesonide extended release for patients with mild to moderate ulcerative colitis who have not responded to 5-ASAs.
 No clinical or cost-effectiveness evidence or evidence-based recommendations were found describing the use of budesonide extended release in patients with moderate to severe ulcerative colitis.
","PeriodicalId":9437,"journal":{"name":"Canadian Journal of Health Technologies","volume":"36 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-10-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135483926","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Medical librarians and information specialists have unique evidence retrieval skills that can help health technology assessment organizations reduce bias in the evidence they use: They identify gaps in mainstream evidence sources and seek out alternatives that provide the perspectives of underrepresented populations. They create complex and efficient database searches that encompass the wide variety of synonyms and phrases used to describe health disparities and inequities. They use sound, logical, and efficient ways to access evidence from paywalled systems while respecting rights of ownership. They critically appraise information systems to determine if they emphasize biases and inequities or create new ones.
{"title":"Equity in Information Retrieval","authors":"Danielle Rabb","doi":"10.51731/cjht.2023.747","DOIUrl":"https://doi.org/10.51731/cjht.2023.747","url":null,"abstract":"Medical librarians and information specialists have unique evidence retrieval skills that can help health technology assessment organizations reduce bias in the evidence they use: They identify gaps in mainstream evidence sources and seek out alternatives that provide the perspectives of underrepresented populations. They create complex and efficient database searches that encompass the wide variety of synonyms and phrases used to describe health disparities and inequities. They use sound, logical, and efficient ways to access evidence from paywalled systems while respecting rights of ownership. They critically appraise information systems to determine if they emphasize biases and inequities or create new ones.","PeriodicalId":9437,"journal":{"name":"Canadian Journal of Health Technologies","volume":"206 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-10-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135740513","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Jamie Anne Bentz, Francesca Brundisini, Danielle MacDougall
This review used a rapid best-fit framework analysis approach to synthesize 9 included studies exploring how people who engage with emergency department (ED) services experience and understand the impacts of ED overcrowding, access block, and boarding on quality of care, patient safety, and the well-being of health care professional learners and staff working in the ED. None of the included studies were conducted in Canada.
The included studies detailed how people who engage with ED services understand the ED as a location that is appropriate for providing short-term treatment to people requiring critical or emergent care, but inappropriate for providing care to patients for extended lengths of time. Study participants described experiencing ED overcrowding, boarding, and access block as transforming the ED into an unsafe environment where the risk of avoidable patient harm increased due to the accelerated depletion of available equipment, space, and human resources. They observed that this unsafe environment led to patients experiencing delayed, missed, and inappropriate care, resulting in potential or actual physical harm, threats to their human rights and dignity, exposures to secondary suffering, reduced satisfaction, and worsening emotional and psychological states.
Participants reported that ED overcrowding, access block, and boarding had, for the most part, negative impacts on health care professional learners and staff working in the ED. Some ED staff reported that these phenomena led them to experience increased exposure to violence and physical harm, emotional and moral distress, dimensions of burnout, and/or missed learning opportunities for health care professional learners. Some ED staff reported experiences of camaraderie and collaboration necessarily forged as a coping mechanism to manage adversity in the context of overcrowding. Amid the challenges experienced within their practice setting, some experienced staff also perceived overcrowding as providing opportunities to exercise and expand their existing knowledge and skills.
Considering these findings, decision-makers seeking to address the adverse impacts of ED overcrowding, access block, and boarding on quality of care and patient safety may explore facilitating the integration of routine preventive care into ED processes; enhancing communication within the ED; optimizing available equipment and space; giving patients information before and during their stay to manage their expectations; and enhancing staff’s access to education and resources necessary to better address the needs of patients who frequently experience extended stays in the ED and require specialized care beyond that which ED staff typically have the training and experience to provide. They may prioritize interventions that alleviate, rather than add to, the workload of ED staff. Additionally, they may assess and explore working conditions in the ED with a lens of promoting the well-being
{"title":"Perspectives and Experiences Regarding the Impacts of Emergency Department Overcrowding: A Rapid Qualitative Review","authors":"Jamie Anne Bentz, Francesca Brundisini, Danielle MacDougall","doi":"10.51731/cjht.2023.746","DOIUrl":"https://doi.org/10.51731/cjht.2023.746","url":null,"abstract":"
 This review used a rapid best-fit framework analysis approach to synthesize 9 included studies exploring how people who engage with emergency department (ED) services experience and understand the impacts of ED overcrowding, access block, and boarding on quality of care, patient safety, and the well-being of health care professional learners and staff working in the ED. None of the included studies were conducted in Canada.
 The included studies detailed how people who engage with ED services understand the ED as a location that is appropriate for providing short-term treatment to people requiring critical or emergent care, but inappropriate for providing care to patients for extended lengths of time. Study participants described experiencing ED overcrowding, boarding, and access block as transforming the ED into an unsafe environment where the risk of avoidable patient harm increased due to the accelerated depletion of available equipment, space, and human resources. They observed that this unsafe environment led to patients experiencing delayed, missed, and inappropriate care, resulting in potential or actual physical harm, threats to their human rights and dignity, exposures to secondary suffering, reduced satisfaction, and worsening emotional and psychological states.
 Participants reported that ED overcrowding, access block, and boarding had, for the most part, negative impacts on health care professional learners and staff working in the ED. Some ED staff reported that these phenomena led them to experience increased exposure to violence and physical harm, emotional and moral distress, dimensions of burnout, and/or missed learning opportunities for health care professional learners. Some ED staff reported experiences of camaraderie and collaboration necessarily forged as a coping mechanism to manage adversity in the context of overcrowding. Amid the challenges experienced within their practice setting, some experienced staff also perceived overcrowding as providing opportunities to exercise and expand their existing knowledge and skills.
 Considering these findings, decision-makers seeking to address the adverse impacts of ED overcrowding, access block, and boarding on quality of care and patient safety may explore facilitating the integration of routine preventive care into ED processes; enhancing communication within the ED; optimizing available equipment and space; giving patients information before and during their stay to manage their expectations; and enhancing staff’s access to education and resources necessary to better address the needs of patients who frequently experience extended stays in the ED and require specialized care beyond that which ED staff typically have the training and experience to provide. They may prioritize interventions that alleviate, rather than add to, the workload of ED staff. Additionally, they may assess and explore working conditions in the ED with a lens of promoting the well-being","PeriodicalId":9437,"journal":{"name":"Canadian Journal of Health Technologies","volume":"18 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-09-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135246994","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class.
The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec.
This review assesses difelikefalin (Korsuva), 50 mcg/mL, IV.
Indication: For the treatment of moderate-to-severe pruritus associated with chronic kidney disease in adult patients on hemodialysis.
& # x0D;CADTH报销审查是对药物或药物类别的临床有效性和成本效益以及患者和临床医生观点的综合评估。
评估结果提供了非约束性建议，这些建议有助于指导加拿大联邦、省和地区政府(魁北克省除外)的报销决定。本综述评估了difelikefalin (Korsuva)， 50 mcg/mL, IV.
适应症:用于成人血液透析患者伴慢性肾脏疾病的中重度瘙痒。
{"title":"Difelikefalin (Korsuva)","authors":"None CADTH","doi":"10.51731/cjht.2023.745","DOIUrl":"https://doi.org/10.51731/cjht.2023.745","url":null,"abstract":"
 CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class.
 The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec.
 This review assesses difelikefalin (Korsuva), 50 mcg/mL, IV.
 Indication: For the treatment of moderate-to-severe pruritus associated with chronic kidney disease in adult patients on hemodialysis.
","PeriodicalId":9437,"journal":{"name":"Canadian Journal of Health Technologies","volume":"40 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-09-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135584954","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
CADTH recommends that Kymriah be reimbursed by public drug plans for the treatment of adults with relapsed or refractory follicular lymphoma (FL) if certain conditions are met.
Kymriah should only be covered to treat adults who have grade 1, 2, or 3a FL whose disease did not respond to a second or later line of treatment, returned within 6 months after 2 or more treatments, or returned after an autologous stem cell transplant (SCT).
Kymriah should only be reimbursed for patients who have not already received a chimeric antigen receptor (CAR) T-cell therapy, are in relatively good health, and the cost of Kymriah is reduced. Kymriah should be prescribed and administered by clinicians with expertise in blood cancers in a hospital setting with adequate resources to treat patients and manage side effects.
{"title":"Tisagenlecleucel (Kymriah)","authors":"None CADTH","doi":"10.51731/cjht.2023.741","DOIUrl":"https://doi.org/10.51731/cjht.2023.741","url":null,"abstract":"
 CADTH recommends that Kymriah be reimbursed by public drug plans for the treatment of adults with relapsed or refractory follicular lymphoma (FL) if certain conditions are met.
 Kymriah should only be covered to treat adults who have grade 1, 2, or 3a FL whose disease did not respond to a second or later line of treatment, returned within 6 months after 2 or more treatments, or returned after an autologous stem cell transplant (SCT).
 Kymriah should only be reimbursed for patients who have not already received a chimeric antigen receptor (CAR) T-cell therapy, are in relatively good health, and the cost of Kymriah is reduced. Kymriah should be prescribed and administered by clinicians with expertise in blood cancers in a hospital setting with adequate resources to treat patients and manage side effects.
","PeriodicalId":9437,"journal":{"name":"Canadian Journal of Health Technologies","volume":"72 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-09-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"136313189","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
CADTH recommends that Brukinsa be reimbursed by public drug plans for the treatment of adult patients with chronic lymphocytic leukemia (CLL) if certain conditions are met.
Brukinsa should only be covered to treat adult patients with previously untreated CLL for whom fludarabine-based treatment is inappropriate or patients with relapsed or refractory (r/r) CLL who have received at least 1 prior systemic therapy. Patients receiving Brukinsa should be in relatively good health (i.e., have a good performance status, as determined by a specialist). Patients who have progressed on a Bruton tyrosine kinase (BTK) inhibitor or patients with prolymphocytic leukemia or Richter’s transformation should not be eligible for coverage.
Brukinsa should only be reimbursed if prescribed by clinicians with expertise and experience in the treatment of CLL and monitoring of therapy and if it is associated with cost savings for drug programs relative to ibrutinib or acalabrutinib. Patients who experience disease progression while taking Brukinsa or who cannot tolerate the drug would not be eligible for continued coverage.
{"title":"Zanubrutinib (Brukinsa)","authors":"None CADTH","doi":"10.51731/cjht.2023.744","DOIUrl":"https://doi.org/10.51731/cjht.2023.744","url":null,"abstract":"
 CADTH recommends that Brukinsa be reimbursed by public drug plans for the treatment of adult patients with chronic lymphocytic leukemia (CLL) if certain conditions are met.
 Brukinsa should only be covered to treat adult patients with previously untreated CLL for whom fludarabine-based treatment is inappropriate or patients with relapsed or refractory (r/r) CLL who have received at least 1 prior systemic therapy. Patients receiving Brukinsa should be in relatively good health (i.e., have a good performance status, as determined by a specialist). Patients who have progressed on a Bruton tyrosine kinase (BTK) inhibitor or patients with prolymphocytic leukemia or Richter’s transformation should not be eligible for coverage.
 Brukinsa should only be reimbursed if prescribed by clinicians with expertise and experience in the treatment of CLL and monitoring of therapy and if it is associated with cost savings for drug programs relative to ibrutinib or acalabrutinib. Patients who experience disease progression while taking Brukinsa or who cannot tolerate the drug would not be eligible for continued coverage.
","PeriodicalId":9437,"journal":{"name":"Canadian Journal of Health Technologies","volume":"101 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-09-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"136313190","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
CADTH recommends that Rinvoq be reimbursed by public drug plans for the treatment of adult patients with moderately to severely active ulcerative colitis (UC) who have demonstrated prior treatment failure (i.e., an inadequate response to, loss of response to, or intolerance to at least 1 of conventional therapy and/or biologic therapy), if certain conditions are met.
Rinvoq should be covered for a similar patient population and in a similar way to other drugs currently reimbursed by public drug plans for the treatment of moderately to severely active UC.
Rinvoq should only be reimbursed if it is prescribed by a physician experienced in treating UC, the dosage does not exceed the product monograph’s recommended dosage, and it is not used in combination with biologics for UC. It should not cost more than other biologics or targeted synthetic drugs covered by the public drug plans for the treatment of moderately to severely active UC.
{"title":"Upadacitinib (Rinvoq)","authors":"None CADTH","doi":"10.51731/cjht.2023.743","DOIUrl":"https://doi.org/10.51731/cjht.2023.743","url":null,"abstract":"
 CADTH recommends that Rinvoq be reimbursed by public drug plans for the treatment of adult patients with moderately to severely active ulcerative colitis (UC) who have demonstrated prior treatment failure (i.e., an inadequate response to, loss of response to, or intolerance to at least 1 of conventional therapy and/or biologic therapy), if certain conditions are met.
 Rinvoq should be covered for a similar patient population and in a similar way to other drugs currently reimbursed by public drug plans for the treatment of moderately to severely active UC.
 Rinvoq should only be reimbursed if it is prescribed by a physician experienced in treating UC, the dosage does not exceed the product monograph’s recommended dosage, and it is not used in combination with biologics for UC. It should not cost more than other biologics or targeted synthetic drugs covered by the public drug plans for the treatment of moderately to severely active UC.
","PeriodicalId":9437,"journal":{"name":"Canadian Journal of Health Technologies","volume":"345 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-09-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"136313191","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：